© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 12, 903-912,
June 20, 2001
© 2001 Oxford University Press
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas
Affiliations of authors: M. E. Wilcox, W. Yang, D. Senger, Z. Q. Shi, P. A. Forsyth, Departments of Oncology and Clinical Neurosciences, University of Calgary, and Tom Baker Cancer Centre, Alberta, Canada; N. B. Rewcastle, Pathology Department, Foothills Hospital, Calgary; D. G. Morris (Departments of Medicine and Oncology), P. M. A. Brasher (Department of Epidemiology, Prevention and Screening), Tom Baker Cancer Centre; R. N. Johnston (Departments of Medical Biochemistry and Oncology), S. Nishikawa, P. W. K. Lee (Departments of Microbiology and Infectious Diseases), University of Calgary.
Correspondence to: Peter A. Forsyth, M.D., F.R.C.P.C., Department of Oncology, Tom Baker Cancer Centre, 1331 29 St., N.W., Calgary, AB, T2N 4N2, Canada (e-mail: peter.forsyth{at}cancerboard.ab.ca).
Background: Reovirus is a naturally occurring oncolytic virus that usurps activated Ras-signaling pathways of tumor cells for its replication. Ras pathways are activated in most malignant gliomas via upstream signaling by receptor tyrosine kinases. The purpose of this study was to determine the effectiveness of reovirus as an experimental treatment for malignant gliomas. Methods: We investigated whether reovirus would infect and lyse human glioma cell lines in vitro. We also tested the effect of injecting live reovirus in vivo on human gliomas grown subcutaneously or orthotopically (i.e., intracerebrally) in mice. Finally, reovirus was tested ex vivo against low-passage cell lines derived from human glioma specimens. All P values were two-sided. Results: Reovirus killed 20 (83%) of 24 established malignant glioma cell lines tested. It caused a dramatic and often complete tumor regression in vivo in two subcutaneous (P = .0002 for both U251N and U87) and in two intracerebral (P = .0004 for U251N and P = .0009 for U87) human malignant glioma mouse models. As expected, serious toxic effects were found in these severely immunocompromised hosts. In a less immunocompromised mouse model, a single intratumoral inoculation of live reovirus led to a dramatic prolongation of survival (compared with control mice treated with dead virus; log-rank test, P<.0001 for both U251N and U87 cell lines). The animals treated with live virus also appeared to be healthier and gained body weight (P = .0001). We then tested the ability of reovirus to infect and kill primary cultures of brain tumors removed from patients and found that it killed nine (100%) of nine glioma specimens but none of the cultured meningiomas. Conclusions: Reovirus has potent activity against human malignant gliomas in vitro, in vivo, and ex vivo. Oncolysis with reovirus may be a potentially useful treatment for a broad range of human cancers.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 Clin. Cancer Res., January 15, 2009; 15(2): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Q. Lun, H. Zhou, T. Alain, B. Sun, L. Wang, J. W. Barrett, M. M. Stanford, G. McFadden, J. Bell, D. L. Senger, et al. Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin Cancer Res., September 15, 2007; 67(18): 8818 - 8827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis Cancer Res., April 1, 2007; 67(7): 3295 - 3300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lun, D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, et al. Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas. J Natl Cancer Inst, November 1, 2006; 98(21): 1546 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ito, H. Aoki, F. Kuhnel, Y. Kondo, S. Kubicka, T. Wirth, E. Iwado, A. Iwamaru, K. Fujiwara, K. R. Hess, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst, May 3, 2006; 98(9): 625 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ochiai, S. A. Campbell, G. E. Archer, T. A. Chewning, E. Dragunsky, A. Ivanov, M. Gromeier, and J. H. Sampson Targeted Therapy for Glioblastoma Multiforme Neoplastic Meningitis with Intrathecal Delivery of an Oncolytic Recombinant Poliovirus Clin. Cancer Res., February 15, 2006; 12(4): 1349 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lun, W. Yang, T. Alain, Z.-Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, et al. Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas Cancer Res., November 1, 2005; 65(21): 9982 - 9990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Steele and C. C. Hauser The Role of Interferon- {alpha} in a Successful Murine Tumor Therapy Experimental Biology and Medicine, July 1, 2005; 230(7): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rudd and G. Lemay Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells J. Gen. Virol., May 1, 2005; 86(5): 1489 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Jeeninga, B. Jan, B. van der Linden, H. van den Berg, and B. Berkhout Construction of a Minimal HIV-1 Variant that Selectively Replicates in Leukemic Derived T-Cell Lines: Towards a New Virotherapy Approach Cancer Res., April 15, 2005; 65(8): 3347 - 3355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kambara, H. Okano, E. A. Chiocca, and Y. Saeki An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain Tumor Cancer Res., April 1, 2005; 65(7): 2832 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Q. Yang, X. Lun, C. A. Palmer, M. E. Wilcox, H. Muzik, Z. Q. Shi, R. Dyck, M. Coffey, B. Thompson, M. Hamilton, et al. Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates Clin. Cancer Res., December 15, 2004; 10(24): 8561 - 8576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Norman, K. Hirasawa, A.-D. Yang, M. A. Shields, and P. W. K. Lee Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection PNAS, July 27, 2004; 101(30): 11099 - 11104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Thirukkumaran, J. M. Luider, D. A. Stewart, T. Cheng, S. M. Lupichuk, M. J. Nodwell, J. A. Russell, I. A. Auer, and D. G. Morris Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation Blood, July 1, 2003; 102(1): 377 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Q. Yang, D. Senger, H. Muzik, Z. Q. Shi, D. Johnson, P. M. A. Brasher, N. B. Rewcastle, M. Hamilton, J. Rutka, J. Wolff, et al. Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma Cancer Res., June 15, 2003; 63(12): 3162 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hirasawa, S. G. Nishikawa, K. L. Norman, M. C. Coffey, B. G. Thompson, C.-S. Yoon, D. M. Waisman, and P. W. K. Lee Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice Cancer Res., January 15, 2003; 63(2): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Alain, K. Hirasawa, K. J. Pon, S. G. Nishikawa, S. J. Urbanski, Y. Auer, J. Luider, A. Martin, R. N. Johnston, A. Janowska-Wieczorek, et al. Reovirus therapy of lymphoid malignancies Blood, December 1, 2002; 100(12): 4146 - 4153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Fathallah-Shaykh Darts in the Dark Cure Animal, but Not Human, Brain Tumors Arch Neurol, May 1, 2002; 59(5): 721 - 724. [Full Text] [PDF]
|
|
|
|
|
|
C. J. A. Ring Cytolytic viruses as potential anti-cancer agents J. Gen. Virol., March 1, 2002; 83(3): 491 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gromeier Viruses as Therapeutic Agents Against Malignant Disease of the Central Nervous System J Natl Cancer Inst, June 20, 2001; 93(12): 889 - 890. [Full Text] [PDF]
|
|